• Parenteral nutrition

Omegaven Generic Name & Formulations

General Description

Fish oil triglycerides 5g/50mL, 10g/100mL; emulsion for IV infusion; contains aluminum.

Pharmacological Class

Fatty acids.

How Supplied

Single-dose bottles (50mL, 100mL)—1, 10


Generic Availability


Omegaven Indications


To provide a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).

Limitations of Use

Not for prevention of PNAC. Not demonstrated that clinical outcomes with Omegaven are a result of omega-6:omega-3 fatty acid ratio.

Omegaven Dosage and Administration


Not indicated.


Individualize. May give alone or as part of PN admixture. Initiate therapy as soon as direct or conjugated bilirubin (DBil) levels ≥2mg/dL in patients expected to be PN-dependent for ≥2 weeks. Determine dose based on energy requirements, age, body wt, tolerance, clinical status, ability to eliminate/metabolize lipids, and additional energy supplied from parenteral, oral, or enteral nutrition. Administer by IV infusion via a central or peripheral vein. Usual dose: max 1g/kg/day. Initiate rate at max 0.05mL/min for first 15–30mins; if tolerated, increase gradually to required rate after 30mins; max 1.5mL/kg/hr (0.15g/kg/hr). Usual infusion duration: 8–24hrs based on patients' clinical status. Can administer until DBil <2mg/dL or until PN no longer required. Hypertriglyceridemia: see full labeling. If TGs remain elevated, consider 0.5–0.75g/kg/day with incremental increase to 1g/kg/day.

Omegaven Contraindications


Fish or egg protein allergy. Severe hemorrhagic disorder due to potential effect on platelet aggregation. Severe hyperlipidemia or severe lipid metabolism disorders characterized by hypertriglyceridemia (serum triglyceride [TG] >1000mg/dL).

Omegaven Boxed Warnings

Not Applicable

Omegaven Warnings/Precautions


Risk of death in preterm infants: see full labeling. Monitor for pleural or pericardial effusion. Correct severe fluid and electrolyte disorders prior to initiating. Measure serum triglycerides at baseline and periodically during treatment. If hypertriglyceridemia (TG >250mg/dL [infants] or >400mg/dL [older children]) develops; consider interrupting for 4hrs and repeat serum TG levels; resume as indicated. Discontinue immediately and treat if hypersensitivity reaction occurs. Increased risk of infection with malnutrition-associated immunosuppression, long-term use, poor catheter maintenance, immunosuppressive effects of other conditions or drugs; monitor and ensure aseptic technique. Severely malnourished: monitor closely for refeeding syndrome. Increased risk of aluminum toxicity (esp. in renal impairment, preterm infants). Monitor fluid and electrolyte status, blood glucose, hepatic and renal function, coagulation parameters, and CBC during treatment. Monitor for essential fatty acid deficiency (EFAD). Pregnancy. Nursing mothers.

Omegaven Pharmacokinetics

See Literature

Omegaven Interactions


Concomitant antiplatelets or anticoagulants: monitor bleeding time periodically. May interfere with lab blood tests (eg, hemoglobin, lactate dehdyrogenase, bilirubin, oxygen saturation).

Omegaven Adverse Reactions

Adverse Reactions

Vomiting, agitation, bradycardia, apnea, viral infection, erythema, rash, abscess, neutropenia, hypertonia, incision site erythema; fat overload syndrome, hypertriglyceridemia.

Omegaven Clinical Trials

See Literature

Omegaven Note

Not Applicable

Omegaven Patient Counseling

See Literature